Zacks Research Issues Negative Estimate for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Stock analysts at Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for shares of Bio-Rad Laboratories in a research report issued on Monday, June 9th. Zacks Research analyst R. Department now expects that the medical research company will earn $2.03 per share for the quarter, down from their prior forecast of $2.14. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $2.60 EPS, FY2025 earnings at $9.37 EPS, Q1 2026 earnings at $2.80 EPS, Q2 2026 earnings at $2.45 EPS, Q3 2026 earnings at $2.64 EPS, Q4 2026 earnings at $2.94 EPS and FY2026 earnings at $10.83 EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. The company had revenue of $585.40 million during the quarter, compared to analysts' expectations of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The firm's revenue for the quarter was down 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.30 EPS.

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, June 8th. UBS Group decreased their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company cut their target price on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a research report on Monday, June 9th. Citigroup cut their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Royal Bank of Canada lowered their target price on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $324.25.

Bio-Rad Laboratories Stock Performance

Shares of NYSE:BIO traded down $4.99 during trading hours on Wednesday, hitting $227.43. The stock had a trading volume of 452,343 shares, compared to its average volume of 330,283. The stock's fifty day simple moving average is $236.37 and its 200 day simple moving average is $281.71. Bio-Rad Laboratories has a 1-year low of $211.43 and a 1-year high of $387.99. The firm has a market capitalization of $6.19 billion, a price-to-earnings ratio of -3.50 and a beta of 0.93. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Institutional Investors Weigh In On Bio-Rad Laboratories

Large investors have recently made changes to their positions in the stock. Empowered Funds LLC bought a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at about $443,000. Asset Planning Inc acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at approximately $33,000. Rhumbline Advisers grew its holdings in shares of Bio-Rad Laboratories by 0.5% during the 4th quarter. Rhumbline Advisers now owns 54,500 shares of the medical research company's stock valued at $17,904,000 after purchasing an additional 264 shares during the last quarter. Principal Securities Inc. grew its holdings in shares of Bio-Rad Laboratories by 1,501.1% during the 4th quarter. Principal Securities Inc. now owns 2,994 shares of the medical research company's stock valued at $984,000 after purchasing an additional 2,807 shares during the last quarter. Finally, Strategic Financial Concepts LLC bought a new stake in Bio-Rad Laboratories during the 4th quarter worth approximately $3,561,000. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.